Transparency - Bristol Myers Squibb

We believe in providing an open environment to help build a foundation of trust and respect among our colleagues, healthcare professionals, patients, stockholders, and the public. Making information available is important as we continue to operate our business to the highest standards, and in keeping with current laws and regulations.

We are firmly focused on Our Mission and take our responsibility for transparency seriously. Sustainability reporting is a clear example of an area in which we will continue to work to increase transparency as we show progress towards our Sustainability 2020 Goals.

At Bristol Myers Squibb we work in partnership with lots of organisations to meet the needs of patients and the NHS. Bristol Myers Squibb is committed to working in partnership with others in a way which is fully compliant with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice. Our objective is to act transparently with all stakeholders and the community at large.

Quick Links

Clinical trials >

UK Transparency

Bristol Myers Squibb is widely recognised for excellence in providing some of the world’s most important medicines for patients. At the same time, we strive to be transparent by providing information about treatments we are studying, whether they are investigational compounds, or new indications for existing marketed products.

Methodologies on What We Are Disclosing

For BMS Methodology document please see the Disclosure UK database hosted on the website of the ABPI

Disclosure Report

For transparency reports covering the latest three years of reportable data, see the Disclosure UK database hosted on the website of the ABPI

If you have a question about Transfers of Value reported by Bristol Myers Squibb, Contact us via transparency_EU@bms.com

NO-GB-2200304
December 2022